Valuation: Outlook Therapeutics, Inc.

Market Cap 114M 102M 93.88M 85.06M 159M 10.82B 162M 1.12B 449M 5.69B 428M 419M 17.95B P/E 2026 *
-0.81x
P/E 2027 * -2.16x
Enterprise Value 114M 102M 93.88M 85.06M 159M 10.82B 162M 1.12B 449M 5.69B 428M 419M 17.95B EV / Sales 2026 *
167x
EV / Sales 2027 * 2.59x
Free-Float
86.07%
Yield 2026 *
-
Yield 2027 * -
1 day-5.15%
1 week-9.86%
Current month-18.38%
1 month-18.38%
3 months-54.99%
6 months+87.24%
Current year-70.37%
1 week 0.45
Extreme 0.45
0.55
1 month 0.44
Extreme 0.4379
0.62
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
2.54
3 years 0.16
Extreme 0.1611
13.32
5 years 0.16
Extreme 0.1611
43.3
10 years 0.16
Extreme 0.1611
699.2
Manager TitleAgeSince
Chief Executive Officer 54 01/07/2025
Director of Finance/CFO 58 01/09/2026
Chief Tech/Sci/R&D Officer - 19/01/2023
Director TitleAgeSince
Director/Board Member 65 11/12/2015
Chairman 41 31/01/2025
Director/Board Member 50 31/10/2017
Date Insider Type Main position Quantity % Market Cap. Importance
1/9/26 Free

Chief Financial Officer

500,000 0.3122%
14/8/26 Buy

Chief Executive Officer

202,020 0.0832%
14/8/26 Buy

Chief Executive Officer

303,030 0.1249%
Change 5-day change 1-year change 3-year change Capi.($)
-5.15%-9.86%-62.25%-95.69% 114M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average -0.21%+5.80%+36.85%+176.12% 39.45B
Weighted average by Cap. +0.18%+5.44%+48.47%+186.05%

Financials

2026 *2027 *
Net sales 683K 611K 562K 510K 953K 64.82M 970K 6.71M 2.69M 34.1M 2.56M 2.51M 108M 44.07M 39.47M 36.31M 32.9M 61.49M 4.18B 62.64M 433M 174M 2.2B 165M 162M 6.94B
Net income -65.1M -58.3M -53.63M -48.59M -90.83M -6.18B -92.53M -640M -257M -3.25B -244M -239M -10.25B -44.43M -39.79M -36.6M -33.17M -62M -4.22B -63.16M -437M -175M -2.22B -167M -163M -7B
Net Debt - -
Projected Income Statement - Annual - Outlook Therapeutics, Inc.
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
30/10/26 US$0.4681 -5.15% 4,794,518
29/10/26 US$0.4935 -9.43% 7,059,523
28/10/26 US$0.5449 +2.85% 2,140,816
27/10/26 US$0.5298 +3.21% 3,262,604
26/10/26 US$0.5133 -1.16% 2,529,683
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Outlook Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.4681USD
Average target price
5.025USD
Spread / Average Target
+973.49%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Outlook Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. OTLK Stock